UT-ICON-HEALTH-&-FITNESS
11.1.2021 12:02:50 CET | Business Wire | Press release
iFit, a global leader in interactive connected fitness technology, today announced the upcoming release of iFit ActivePulse automatic heart rate training. iFit’s cutting edge technology uses complex algorithms so an iFit subscriber’s heart rate controls the treadmill in real time, automatically adjusting the speed and incline to maintain the optimal heart rate zone.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005174/en/
iFit’s game-changing innovation removes the guesswork from heart rate training, by allowing a member’s heart rate to automatically scale and tailor iFit’s vast library of workouts to their individual fitness levels and goals. iFit has applied for patent protection on ActivePulse, which will be available on all iFit-controlled NordicTrack® , ProForm® and Freemotion® treadmills.
Until now, the benefits of heart rate training have hinged on how well a person is able to manually monitor and adjust their effort in order to remain in a particular heart rate zone. In contrast, iFit ActivePulse creates a real-time feedback loop between a user’s measured heart rate and the treadmill’s speed and incline.
iFit ActivePulse heart rate training keeps the user in their optimal zone, while enabling them to accomplish their fitness goals by targeting different heart rate zones.
“ActivePulse lets each iFit customer's heart rate personalize their treadmill workout without the complicated calculations and constant manual adjustments that have long been associated with heart rate training,” said Mark Watterson, President of iFit. “ActivePulse provides a workout that is catered not just to a member; it is catered to that member based on how their heart rate is functioning during the workout.”
Daily variables such as hydration, sleep, and stress have a direct impact on heart rate, therefore the effectiveness of a given workout can vary from one day to the next based on heart rate performance. iFit ActivePulse scales and tailors the intensity of any iFit program to optimize the workout based on their heart rate at that moment—even incorporating advanced algorithms to gradually “learn” their unique behavioral patterns over time.
Heart rate training—the concept of exercising within predetermined ranges (or “zones”) of a user’s maximum heart rate to achieve specific fitness goals—has been used by elite athletes and coaches around the world for more than 30 years. With various heart rate zones corresponding to fitness goals like building endurance, and promoting recovery, heart rate training is widely accepted as the most intelligent way to achieve consistent and measurable progress towards specific fitness goals.
iFit ActivePulse is compatible with leading Bluetooth® heart rate monitors with broadcast functionality, including the iFit SmartBeat™ forearm heart rate monitor, as well as third-party devices from brands including Polar®, Garmin®, Wahoo® and WHOOP®.
Included with all iFit memberships, ActivePulse will be available on all iFit-enabled NordicTrack, ProForm and Freemotion treadmills via an automatic iFit software update in January 2021. The feature will become available for stationary bikes, rowers, and ellipticals from NordicTrack, ProForm and Freemotion soon thereafter.
About iFit
iFit is the patented connected fitness platform that powers NordicTrack, ProForm and Freemotion equipment. ICON, the creator and owner of iFit, pioneered interactive fitness and was issued its first of many patents for its training technology in the early 2000s. Founded with the belief that the majority of consumers would benefit from an interactive, personal training experience at home, iFit’s trainer-led, streaming workouts are now trusted by millions of consumers around the world.
iFit offers workout options for every fitness level and interest—from bodyweight training, boxing, HIIT, yoga, Pilates and more—to connected fitness workouts on NordicTrack home equipment. Patented interactive technology allows iFit Trainers to create workouts for iFit members that automatically adjust the member’s incline, decline, speed and resistance in sync with iFit’s streaming workouts. iFit interactive content is available on NordicTrack, ProForm and Freemotion treadmills, stationary bikes, rowers, ellipticals, strength machines and the iFit app.
ICON Health & Fitness, Inc. is a global health and fitness leader and owner of iFit, NordicTrack, ProForm, Freemotion and other fitness brands. Based in Logan, Utah, the 43-year old company has a multi-decade heritage of innovation and quality. ICON currently holds more than 330 patents, with more than 80 pending, and its products are sold in 116 countries. iFit workouts are streamed in English, Spanish, French and Mandarin Chinese, with more languages planned for 2021.
Join the discussion @iFit , @NordicTrack and @ProForm
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005174/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cegid Closes Acquisition of Shine to Create Europe's First Complete AI-Driven Platform for SMBs and Accountants8.6.2026 09:28:00 CEST | Press release
Accelerates Cegid’s trajectory to become the leading European financial solutions hub integrating e-invoicing, accounting, digital finance, payment services and accounts, and HR solutionsTransaction supported by new €1.1 billion debt financing facility secured from leading direct credit funds, underscoring Cegid’s strong business performance and unique leadership positioning in rapidly evolving software sector Cegid, a European leader in cloud management solutions for professionals in the finance (treasury, tax, ERP), human resources (payroll, talent management), accountancy, retail and entrepreneurship sectors, today announced the completion of its acquisition of Shine. The transaction creates the first fully integrated, cloud-native and AI-driven financial hub for SMBs and accounting professionals in Europe. Shine – a fast-growing European fintech unicorn providing electronic invoicing, accounting, business accounts, and payroll software to small and medium-sized businesses across Eu
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
